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We have been involved in the development of cancer
immunotherapy using dendritic cells (DCs) manipulated
to induce better immune responses. Our strategies include
the usage of the agent to induce desirable maturation of
DCs in culture and the genetic modification of DCs to
have better function in situ. We have been developing
immune-gene therapy with DCs genetically modified to
continuously express IL-12. In this study, we investigated
whether bone marrow-derived dendritic cells adenovirally
transduced with genes encoding murine IL-12 combined
with anti-CTLA-4 monoclonal antibody (Ad-IL-12-DCs)
have significant therapeutic benefits for anti-tumor immu-
notherapy. Ad-IL-12-DCs was confirmed to express bioac-
tive IL-12 proteins at high levels, and treatment with
Ad-IL-12-DCs and anti-CTLA-4 monoclonal antibody
showed enhanced anti-tumor effects and induced tumor-
specific cytotoxic T lymphocyte responses in vivo. As a
consequence of these stimulatory effects, combined
treatment with DC vaccine and anti-CTLA-4 monoclonal
antibody accomplished increased anti-tumor effects when
compared with either mono-therapy. The information
related to these trials would be useful to develop effective
immunotherapy against cancer.
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